Symposium Presentations & Outcomes

The Symposium & Summit was attended by 72 delegates from 26 stakeholder organisations. The enthusiasm and commitment to improving quality and safety was palpable throughout the day and demonstrated through both positive collaboration and constructive compromise.

Thank-you to all that attended, we look forward to continuing to work with you in the future.

Please find below a summary of key outcomes and links to downloadable materials and information from the various sessions.

Email contact details for speakers

Delegate List

Standardised Drug Infusions

Presentations

Opening & Overview – Adam Sutherland

DELPHI Results

Outcome of Workshops

Consensus was achieved on 16/20 medicines. Of those medicines where consensus was not achieved this was primarily in those concentrations that would be used in the neonatal care context, and it was possible to identify two potential concentrations which would facilitate a binary choice exercise. The proposed clonidine concentrations were unanimously rejected by the sedation work group as being unworkable and unsafe. An alternative range was proposed. Concerns were also raised about the risk of ten-fold error with dinoprostone. All these will be entered into a binary choice survey as follows:

The following choices will be posed:

Morphine for preterm infants:
Morphine for infants:
Clonidine for all patients:
Dinoprostone for infants:
40 or 100micrograms/ml
100 or 400micrograms/ml
6, 12 and 40micrograms/ml 1microgram/ml and 10microgram/ml

Three drugs were removed from the consensus framework: ketamine, sodium nitroprusside (SNP) and glyceryl trinitrate (GTN). There was a perceived lack of clinical usage (GTN), or usage was diverse and “niche” (ketamine). SNP was withdrawn as the consensus group was unable to discuss the concentration ranges. As an unlicensed medicine in the UK it was reasonable to withdraw it from the framework. This is supported methodologically as isoprenaline was withdrawn from the framework at the EAG stage for similar reasons.

It was agreed that the last three drugs, on which a consensus couldn’t be reached, would be presented for feedback from all delegates. Please take the opportunity to take part in this process by completing the follow up survey here. It should not take any longer than 15 minutes to complete.

Please complete the survey by midnight 24 March.